Message 18037683
CAMBRIDGE, Mass., Sept. 26 /PRNewswire-FirstCall/ -- Hybridon, Inc. (OTC Bulletin Board: HYBN - News) announced today that its researchers have published data on novel DNA molecules that stimulate the immune system with increased potency and selectivity. These molecules, which utilize a proprietary structure, have the potential to combat a wide variety of disease conditions, including cancer, infectious disease and asthma/allergies.
The in vitro and in vivo research data, published in the September, 2002 issue of Biochemical and Biophysical Research Communications, show that these second-generation synthetic CpG immunomodulators have significantly increased metabolic stability as compared to the native compound, and induce higher secretion of disease fighting IL-12, with minimal induction of pro-inflammatory IL-6. The paper further discusses using Hybridon's chemistries to design molecules that would stimulate the induction of other cytokines in a selective manner to treat specific diseases. In effect, the Hybridon molecules are intentionally causing a shift between the two types of immune response, the so-called Th-1 and Th-2 responses, towards Th-1, thereby allowing more effective treatment of certain disease conditions. snip.... |
